Literature DB >> 18328061

Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease.

L Baronciani1, A B Federici, G Cozzi, S La Marca, M Punzo, V Rubini, M T Canciani, P M Mannucci.   

Abstract

Missense mutations are not considered a common cause of type 3 von Willebrand's disease (VWD), the most severe defect of von Willebrand factor (VWF) characterized by undetectable levels of this protein in plasma and platelets. Nevertheless, several missense mutations have been identified in these patients. In this study, we report the cases of two Italian patients with type 3 VWD, both compound heterozygotes for different missense mutations and null alleles, p.D141Y/c.2016_2019del and p.C275S/p.W222X. We performed in vitro expression studies of the candidate missense mutations, both located in the D1 domain of VWF propeptide, to confirm their link with the disease and to understand the mechanisms of type 3 VWD responsible in these patients. Mutant and wild-type (WT) expression vectors were used for transient transfection and co-transfection studies in COS-7 cells. Single construct transfections of both missense mutations showed a strongly reduced but detectable secretion of recombinant (r)VWFs (approximately 15% of WT), with essentially only dimers being visualized on multimeric analysis. As expected, expression of a single construct of either mutation with the WT, showed mildly reduced secretion (approximately 40% of WT) and a full set of multimers. These expression studies indicate that the two amino acids D141 and C275 are key residues in the tertiary structure of the VWF propeptide. Their replacement with a tyrosine and a serine, respectively, might compromise propeptide folding, affecting both its intracellular survival and its capacity to mediate multimerization. Co-expression of hybrid rVWFs confirmed the recessive inheritance pattern of these missense mutations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328061     DOI: 10.1111/j.1365-2516.2008.01682.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  8 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 2.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

3.  The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles.

Authors:  M Bowman; A Tuttle; C Notley; C Brown; S Tinlin; M Deforest; J Leggo; V S Blanchette; D Lillicrap; P James
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

4.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

5.  Mutations in the D1 domain of von Willebrand factor impair their propeptide-dependent multimerization, intracellular trafficking and secretion.

Authors:  Jie Yin; Zhenni Ma; Jian Su; Jiong-Wei Wang; Xiaojuan Zhao; Jing Ling; Xia Bai; Wanyan Ouyang; Zhaoyue Wang; Ziqiang Yu; Changgeng Ruan
Journal:  J Hematol Oncol       Date:  2015-06-20       Impact factor: 17.388

6.  [The function and clinical value of Von Willebrand factor propeptide].

Authors:  Jie Yin; Changgeng Ruan
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2015-10

7.  Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.

Authors:  Nina Borràs; Gerard Orriols; Javier Batlle; Almudena Pérez-Rodríguez; Teresa Fidalgo; Patricia Martinho; María Fernanda López-Fernández; Ángela Rodríguez-Trillo; Esther Lourés; Rafael Parra; Carme Altisent; Ana Rosa Cid; Santiago Bonanad; Noelia Cabrera; Andrés Moret; María Eva Mingot-Castellano; Nira Navarro; Rocío Pérez-Montes; Sally Marcellin; Ana Moreto; Sonia Herrero; Inmaculada Soto; Núria Fernández-Mosteirín; Víctor Jiménez-Yuste; Nieves Alonso; Aurora de Andrés-Jacob; Emilia Fontanes; Rosa Campos; María José Paloma; Nuria Bermejo; Ruben Berrueco; José Mateo; Karmele Arribalzaga; Pascual Marco; Ángeles Palomo; Nerea Castro Quismondo; Belén Iñigo; María Del Mar Nieto; Rosa Vidal; María Paz Martínez; Reyes Aguinaco; Jesús María Tenorio; María Ferreiro; Javier García-Frade; Ana María Rodríguez-Huerta; Jorge Cuesta; Ramón Rodríguez-González; Faustino García-Candel; Manuela Dobón; Carlos Aguilar; Francisco Vidal; Irene Corrales
Journal:  Haematologica       Date:  2018-10-25       Impact factor: 9.941

8.  The dominant p.Thr274Pro mutation in the von Willebrand factor propeptide causes the von Willebrand disease type 1 phenotype in two unrelated patients.

Authors:  Maria Teresa Pagliari; Luciano Baronciani; Chiara Cordiglieri; Paola Colpani; Giovanna Cozzi; Simona M Siboni; Flora Peyvandi
Journal:  Haemophilia       Date:  2022-01-22       Impact factor: 4.263

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.